Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sodium-glucose Co-transporter 2 Inhibitors Effects in Failing Heart Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03977116
Recruitment Status : Completed
First Posted : June 6, 2019
Last Update Posted : March 3, 2020
Sponsor:
Information provided by (Responsible Party):
Celestino Sardu, University of Campania "Luigi Vanvitelli"

Brief Summary:
SLGT2 therapy is safety used in heart failure (HF) patients with depressed left ventricle ejection fraction (LVEF) and diabetes mellitus (DM). These patients experience higher rate of ventricular arrhythmias (VA), that are a leading cause of cardiac arrest and mortality. However, these patients are treated by implantable cardioverter defibrillator (ICD) and cardiac resynchronization with defbrillator devices (CRTd) implant. In this setting, the catheter ablation (CA) treatment has been used to reduce the ventricular arrhythmias and the ICD/CRTds' interventions, and to prevent mortality events in these' patients. On other hand, still a higher percentage of patients result as non responders to an ablative approach with higher acute and long term mortality rate. Therefore, in the present study in a population of HF patients (DM vs. non DM patients) affected by VA, authors will investigate the effects of CA on mortality rate at 12 months of follow up. In addition, authors would demonstrate the ameliorative effects of new hypoglycemic drugs in addition to CA in patients with DM. However, after CA the patients with DM will be randomly assigned to SGLT2 therapy vs. placebo. Indeed, study hypothesis will be that, a) DM vs. non DM patients might have higher mortality rate after CA; b) patients with DM treated by CA plus SLGT2 therapy vs. patients with DM treated by CA plus placebo might experience a lower rate of mortality at 1 year of follow-up.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Heart Failure Ventricular Arrythmia Drug: SLGT2 Drug: Placebo Phase 4

Detailed Description:
SLGT2 therapy is safety used in heart failure (HF) patients with depressed left ventricle ejection fraction (LVEF) and diabetes mellitus (DM). Indeed, in these patients SGLT2 therapy reduces hospital admission for heart failure and mortality rate. To date, these patients experience higher rate of ventricular arrhythmias (VA), that are a leading cause of cardiac arrest and mortality. However, as indicated by international guidelines, these patients can be treated by implantable cardioverter defibrillator (ICD) and CRTd as primary and/or secondary prevention therapy. Consequently, the effectiveness of ICD and CRTd is to treat sustained VA, and to reduce cardiac arrest events and mortality. Indeed, ICDs/CRTds' anti-tachycardia pacing and shocks can interrupt VA, and this might prevent a cardiac arrest event. This therapeutic effect can positively impact on acute and long term patients' survival. On other hand, authors showed that, continuous VA events and ICDs' interventions are causes of reduced patients' life expectancy in HF patients. This worse prognosis is particularly evidenced in failing heart patients with DM as compared to patients without DM. In this setting, the catheter ablation (CA) treatment has been used to reduce the ventricular arrhythmias and the ICDs/CRTds' interventions, and to prevent mortality events in these patients. On other hand, still a higher percentage of patients result as non responders to an ablative approach with higher acute and long term mortality rate. Among these non responders patients to an ablative approach, DM is a negative prognostic factor. Therefore, in the present study in a population of HF patients (DM vs. non DM patients) with VA authors will investigate the effects of CA on mortality rate at 12 months of follow up. In addition, authors would like to demonstrate the ameliorative effects of new hypoglycemic drugs in addition to CA in patients with DM. However, after CA the patients with DM will be randomly assigned to SGLT2 therapy vs. placebo. Indeed, study hypothesis will be that, a) DM vs. non DM might have higher mortality rate after CA; b) patients with DM treated by CA plus SLGT2 therapy vs. patients with DM treated by CA plus placebo might experience a lower rate of mortality at 1 year of follow-up. Therefore, study aim will be to demonstrate a reduction of VA, ICDs/CRTds' interventions, and mortality in patients with DM treated by CA plus SLGT2 therapy vs. patients with DM treated by CA plus placebo at 12 months of follow-up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Clinical Outcomes and Long Term Effects of Sodium-glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Failing Heart Patients With Implantable Cardioverter Defibrillator Undergoing Trans-catheter Ablation for Ventricular Arrhythmias.
Actual Study Start Date : January 1, 2017
Actual Primary Completion Date : January 1, 2019
Actual Study Completion Date : March 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: heart failure patients with diabetes treated by SGLT2 drugs
Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received SLGT2 therapy.
Drug: SLGT2
These patients will receive SLGT2 therapy after catheter ablation.

Placebo Comparator: heart failure patients with diabetes treated by placebo
Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received placebo therapy.
Drug: Placebo
These patients will receive placebo therapy after catheter ablation.




Primary Outcome Measures :
  1. all cause deaths [ Time Frame: 12 months ]
    after the intervention authors will evaluate all cause of deahs

  2. cardiac deaths [ Time Frame: 12 months ]
    after the intervention authors will evaluate the cause of cardiac deahs

  3. ventricular arrhythmias recurrence [ Time Frame: 12 months ]
    after the intervention authors will evaluate the cases of ventricular arrhythmias recurrences


Secondary Outcome Measures :
  1. hospitalization for heart failure worsening [ Time Frame: 12 months ]
    after the intervention authors will evaluate the causes of hospital re-admission for heart failure worsening



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • heart failure (HF) under optimal maximal drug therapy with NYHA functional II-III;
  • HF with prior echocardiographic evidence of left ventricular systolic dysfunction (LVEF <35 % or subjective assessment of LV dysfunction that is mild or worse);
  • patients under furosemide 80 mg daily or less, or equivalent loop diuretic;
  • patients with stable HF symptoms for at least 3 months prior to consent;
  • patients on stable therapy for HF for at least 3 months prior to consent;
  • patients without hospitalization for HF for at least 3 months prior to consent;
  • Ischemic and non ischemic dilated cardiomiopathy diagnosis;
  • patients with internal cardioverter defibrillator (ICD);
  • patients with cardioverter resynchronization therapy and defibrillator (CRTd);
  • patients with diagnosis of diabetes mellitus (DM);
  • patients aged >18 years and <75 years

Exclusion Criteria:

  • Patients without ICD;
  • patients without previous event of ventricular arrhythmia (VA);
  • patients without indication to receive catheter ablation (CA) for VA;
  • patients with type 1 diabetes mellitus;
  • severe hepatic disease, renal disease defined as chronic kidney disease stage 3b or worse (i.e. glomerular filtration rate <45 ml/min);
  • systolic blood pressure <95 mmHg at screening visit;
  • screening HbA1c <6.0 %;
  • patients unable to walk or to perform cardio pulmonary exercise testing or six minute walking test;
  • malignancy (receiving active treatment) or other life threatening diseases;
  • pregnant or lactating women;
  • patients who have participated in any other clinical trial of an investigational medicinal product within the previous 30 days;
  • patients who were unable to give informed consent;
  • any other reason considered by a study physician to be inappropriate for inclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03977116


Locations
Layout table for location information
Italy
Raffaele Marfella
Naples, Italy, 80138
Sponsors and Collaborators
University of Campania "Luigi Vanvitelli"
Layout table for additonal information
Responsible Party: Celestino Sardu, clinical professor, University of Campania "Luigi Vanvitelli"
ClinicalTrials.gov Identifier: NCT03977116    
Other Study ID Numbers: SecondUNI 05.06.2019
First Posted: June 6, 2019    Key Record Dates
Last Update Posted: March 3, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arrhythmias, Cardiac
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Heart Diseases
Cardiovascular Diseases
Pathologic Processes